ArticleCardiovascular and interventional radiology2025
Impact of Sarcopenia on Outcomes Following Endovascular Treatment of Patients with Pelvic Venous Insufficiency.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "Impact of Sarcopenia on Outcomes Following Endovascular Treatment of Patients with Pelvic Venous Insufficiency".Cardiovascular and interventional radiology · 2025Article
- Genetically Predicted Muscle Mass and Function in Relation to Deep Vein Thrombosis: A Two-step Mendelian Randomization Study Highlighting the Mediating Role of BMI.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the influence of sarcopenia on the outcomes of endovascular treatment in patients with pelvic venous insufficiency (PVI). MATERIAL AND
methodsA retrospective analysis was conducted on 62 female patients who underwent endovascular treatment for PVI between January 2012 and July 2020. The patients were evaluated using the Visual Analog Scale (VAS) for chronic pelvic pain, both before treatment and three months post-treatment. A successful treatment outcome was defined as a reduction in pelvic pain by 50% or more. Sarcopenia was diagnosed based on the skeletal muscle mass index (SMI) of the patients.
resultsSarcopenia was present in 20 (32.3%) patients. There was no significant difference in preprocedural VAS scores between sarcopenic and non-sarcopenic patients (36.2 ± 16.9 vs. 34.9 ± 16.1, p = 0.781). However, non-sarcopenic patients achieved a significantly greater reduction in VAS scores post-treatment (67.6 ± 22.4% vs. 53.1 ± 24.4%, p = 0.025). A moderate negative correlation was observed between sarcopenia and successful treatment outcomes (r = -0.365, p = 0.004).
conclusionSarcopenia negatively impacts the effectiveness of endovascular treatment in patients with PVI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.